Literature DB >> 26228449

Heart failure in patients with diabetes undergoing primary percutaneous coronary intervention.

Samia Massalha1, Lior Luria1, Arthur Kerner2, Ariel Roguin2, Eitan Abergel1, Haim Hammerman2, Monther Boulos2, Robert Dragu1, Michael R Kapeliovich2, Rafael Beyar2, Eugenia Nikolsky2, Doron Aronson3.   

Abstract

INTRODUCTION: Diabetes mellitus is associated with increased risk after acute coronary syndromes. Primary percutaneous coronary intervention is the most effective method of reperfusion for acute ST-elevation myocardial infarction and can limit the ischaemic damage to the left ventricle. However, there are few data on the impact of diabetes mellitus on the risk of heart failure following primary percutaneous coronary intervention.
METHODS: We studied 958 ST-elevation myocardial infarction patients treated with primary percutaneous coronary intervention, of whom 263 (27.5%) had diabetes mellitus, with 67 (7.0%) treated with insulin. The primary end points of the study were re-admission for heart failure. Secondary end points were all-cause mortality and recurrent infarctions. The follow-up period was 5 years after hospital discharge.
RESULTS: The cumulative incidence of re-admission for heart failure was 8.4%, 15.2% and 26.7% in patients without diabetes mellitus, non-insulin-treated and insulin-treated diabetes mellitus, respectively. Compared with patients without diabetes mellitus, the adjusted hazard ratio for heart failure was 1.95 (95% confidence intervals 1.30-2.93) and 3.09 (95% confidence intervals 1.71-5.60) in non-insulin-treated and insulin-treated diabetes mellitus, respectively. The corresponding hazard ratios for mortality were 1.03 (95% confidence intervals 0.68-1.55) and 2.04 (95% confidence intervals 1.22-3.42), respectively. There was a J-shaped association between fasting glucose levels in the acute phase and risk of mortality (P=0.0001) and a direct association with heart failure (P=0.03).
CONCLUSION: Despite modern treatment of ST-elevation myocardial infarction and high levels of guideline-based medical care, diabetes mellitus had an independent adverse effect on the risk of re-admissions for heart failure, which was particularly high among insulin-treated patients. © The European Society of Cardiology 2015.

Entities:  

Keywords:  Diabetes; heart failure; myocardial infarction; primary angioplasty; treatment outcome

Mesh:

Substances:

Year:  2015        PMID: 26228449     DOI: 10.1177/2048872615598632

Source DB:  PubMed          Journal:  Eur Heart J Acute Cardiovasc Care        ISSN: 2048-8726


  3 in total

Review 1.  Antioxidant Cardioprotection against Reperfusion Injury: Potential Therapeutic Roles of Resveratrol and Quercetin.

Authors:  Ramón Rodrigo; Catalina Retamal; Denisse Schupper; Diego Vergara-Hernández; Sarmistha Saha; Elisabetta Profumo; Brigitta Buttari; Luciano Saso
Journal:  Molecules       Date:  2022-04-15       Impact factor: 4.927

Review 2.  Comparing the adverse clinical outcomes in patients with non-insulin treated type 2 diabetes mellitus and patients without type 2 diabetes mellitus following percutaneous coronary intervention: a systematic review and meta-analysis.

Authors:  Nuo Li; Ye-Gui Yang; Meng-Hua Chen
Journal:  BMC Cardiovasc Disord       Date:  2016-11-25       Impact factor: 2.298

3.  Visit-to-visit fasting plasma glucose variability is associated with left ventricular adverse remodeling in diabetic patients with STEMI.

Authors:  Chen Die Yang; Ying Shen; Feng Hua Ding; Zhen Kun Yang; Jian Hu; Wei Feng Shen; Rui Yan Zhang; Lin Lu; Xiao Qun Wang
Journal:  Cardiovasc Diabetol       Date:  2020-09-02       Impact factor: 9.951

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.